Horizon Care Center in Arverne, NY

Horizon Care Center is a medicare and medicaid certified nursing home in Arverne, New York. It is located in Queens county at 64 11 Beach Channel Drive, Arverne, New York 11692. You can reach out to the office of Horizon Care Center via phone at (718) 945-0700. This skilled nursing facility has 280 federally certified beds with average occupancy rate of 79.21%. Its legal business name is Ocean Gardens Nursing Facility, Inc. and has the following ownership type - For Profit - Corporation.

Horizon Care Center (Medicare CCN 335738) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1992 (32 years certified) and the last quality survey was conducted in May, 2021.

Name	Horizon Care Center
Location	64 11 Beach Channel Drive, Arverne, New York
Certified By	Medicare and Medicaid
No. of Certified Beds	280
Occupancy Rate	79.21%
Medicare ID (CCN)	335738
Legal Business Name	Ocean Gardens Nursing Facility, Inc.
Ownership Type	For Profit - Corporation

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Horizon Care Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1528052180
Organization Name	OCEAN GARDENS NURSING FACILITY, INC.
Doing Business As	HORIZON CARE CENTER
Address	64-11 Beach Channel Dr, Arverne, NY 11692
Phone Number	718-345-0700

News Archive

New drug treatment linked to higher bladder compliance after spinal cord injury

Researchers have shown that compared to placebo, a drug treatment intended to prevent remodeling of the bladder wall and given within 48 hours after spinal cord injury (SCI) in dogs was associated with significantly higher bladder compliance.

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

LRI's innovative discovery to predict lupus receives license for clinical laboratory development

A discovery made by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at the University of Minnesota has been licensed to a major clinical laboratory for development and could soon result in a test that quickly and easily enables patients and their physicians to determine when a lupus flare is imminent.

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

FDA clears Meridian Bioscience's new Clostridium difficile assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard C. difficile GDH.

Read more Medical News

› Verified 3 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Horizon Care Center are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Horizon Care Center give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

New drug treatment linked to higher bladder compliance after spinal cord injury

Researchers have shown that compared to placebo, a drug treatment intended to prevent remodeling of the bladder wall and given within 48 hours after spinal cord injury (SCI) in dogs was associated with significantly higher bladder compliance.

Immunotherapy is better than chemotherapy as first-line treatment for advanced head and neck cancer

Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial.

LRI's innovative discovery to predict lupus receives license for clinical laboratory development

A discovery made by Lupus Research Institute-funded investigator Emily Baechler Gillespie, PhD, at the University of Minnesota has been licensed to a major clinical laboratory for development and could soon result in a test that quickly and easily enables patients and their physicians to determine when a lupus flare is imminent.

Celtic, Resolvyx enter option agreement for RX-10045 to treat dry eye syndrome

Celtic Therapeutics Holdings L.P. a successor firm to Celtic Pharma, and Resolvyx Pharmaceuticals, Inc. (Resolvyx) announced today that they have entered into an option agreement relating to Resolvyx's RX-10045, a late-stage program for the treatment of dry eye syndrome and other ophthalmic conditions.

FDA clears Meridian Bioscience's new Clostridium difficile assay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced it has received FDA clearance for a new Clostridium difficile assay, ImmunoCard C. difficile GDH.

Read more Medical News

› Verified 3 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	0
Total Amount of Fines in Dollars	$0
Number of Payment Denials	0
Total Number of Penalties	0

The resident survey data of Horizon Care Center is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	14.14	14.46
Percentage of long-stay residents who lose too much weight	7.83	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	51.24	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	0.59	1.79
Percentage of long-stay residents with a urinary tract infection	0.12	2.65
Percentage of long-stay residents who have depressive symptoms	11.11	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	2.05	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	89.63	93.87
Percentage of long-stay residents who received an antipsychotic medication	6.58	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	29.57	83.88
Percentage of short-stay residents who newly received an antipsychotic medication	3.03	1.79
Percentage of long-stay residents whose ability to move independently worsened	27.68	17.09
Percentage of long-stay residents who received an antianxiety or hypnotic medication	13.76	19.7
Percentage of high risk long-stay residents with pressure ulcers	23.19	7.32
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine	91.69	95.98